Eli Lilly and Company (NYSE:LLY) Shares Sold by Farmers National Bank

Farmers National Bank cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,030 shares of the company’s stock after selling 45 shares during the period. Farmers National Bank’s holdings in Eli Lilly and Company were worth $2,743,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. J. W. Coons Advisors LLC lifted its holdings in Eli Lilly and Company by 4.0% in the fourth quarter. J. W. Coons Advisors LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after purchasing an additional 90 shares during the period. Holderness Investments Co. lifted its holdings in shares of Eli Lilly and Company by 3.6% in the fourth quarter. Holderness Investments Co. now owns 1,145 shares of the company’s stock valued at $667,000 after buying an additional 40 shares during the period. Capital International Investors boosted its stake in Eli Lilly and Company by 8.1% during the fourth quarter. Capital International Investors now owns 6,636,833 shares of the company’s stock valued at $3,868,559,000 after buying an additional 497,079 shares in the last quarter. Capital International Sarl grew its holdings in Eli Lilly and Company by 9.9% during the fourth quarter. Capital International Sarl now owns 113,479 shares of the company’s stock worth $66,149,000 after acquiring an additional 10,184 shares during the period. Finally, Capital Research Global Investors raised its position in Eli Lilly and Company by 4.5% in the fourth quarter. Capital Research Global Investors now owns 7,577,592 shares of the company’s stock worth $4,417,120,000 after acquiring an additional 325,342 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 93,593 shares of the stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $918.64, for a total value of $85,978,273.52. Following the transaction, the insider now owns 97,153,810 shares in the company, valued at $89,249,376,018.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 355,962 shares of company stock worth $331,267,535 in the last three months. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Trading Down 0.2 %

Shares of NYSE:LLY opened at $884.55 on Wednesday. The firm has a fifty day moving average of $896.62 and a two-hundred day moving average of $845.90. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12-month low of $516.57 and a 12-month high of $972.53. The firm has a market capitalization of $840.68 billion, a P/E ratio of 130.27, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. On average, equities analysts expect that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on LLY shares. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Bank of America raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Berenberg Bank upped their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Finally, Citigroup initiated coverage on Eli Lilly and Company in a report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 target price on the stock. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $977.35.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.